Unrelated cord blood transplantation for patients with adult T-cell leukemia/lymphoma: experience at a single institute

作者：Nakamura Takayuki; Oku Eijiro; Nomura Kei; Morishige Satoshi; Takata Yuka; Seki Ritsuko; Imamura Rie; Osaki Koichi; Hashiguchi Michitoshi; Yakushiji Kazuaki; Mouri Fumihiko; Mizuno Shinichi; Yoshimoto Koji; Ohshima Koichi; Nagafuji Koji^*; Okamura Takashi

来源：International Journal of Hematology, 2012, 96(5): 657-663.

DOI：10.1007/s12185-012-1177-8

• Adult T-cell leukemia/lymphoma
• Cord blood transplantation
• HTLV-1

We report the results of unrelated cord blood transplantation (UCBT) for patients with adult T-cell leukemia/lymphoma (ATLL) conducted in our single institute. Ten patients with ATLL (nine acute and one lymphoma-type) received UCBT during the period from August 2003 to July 2011. The median age at the time of diagnosis of ATLL was 51 years (range 37-64). The median period from diagnosis of ATLL to UCBT was 130 days (range 94-344). Conditioning regimens were myeloablative for six and reduced intensity for four. The median number of infused nucleated cells and CD34 positive cells were 2.52 x 10(7)/kg and 1.04 x 10(5)/kg, respectively. There was no engraftment failure. Three patients developed grade II acute graft versus host disease, and four developed grade III. The estimated 2-year overall survival was 40 % (95 % CI 12-67 %). Four of six chemosensitive patients prior to UCBT survived for 1035, 793, 712, and 531 days post-UCBT, respectively. There were no survivors among the four chemorefractory patients prior to UCBT. Our data indicates that UCBT is feasible and provides long-term survival in patients with chemosensitive ATLL.

• 出版日期2012-11